CATHERINE GRIMSLEY: Open Payments
NPI 1609543933 · SIOUX CITY, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$274 in 16 payments from 9 companies in 2025. Trend: 2023 $441 · 2024 $522 · 2025 $274
Food & beverage: $274
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 3 | $55 |
| ABBVIE INC. | 3 | $48 |
| Alkermes, Inc. | 2 | $39 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $30 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Novo Nordisk Inc | 1 | $16 |
| Amgen Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
Products named: AUSTEDO XR, ARISTADA, FANAPT, CAPLYTA, VRAYLAR, KEVEYIS, UBRELVY, Wegovy.
Industry payments across IA — which companies pay providers there.
